FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joep Lange

Research Profile

Disorders

Living Beings

HIV-1

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

CD4-Positive T-Lymphocytes

Co-author Network

Publications

TOP 3
Natalie V S Vinkeles Melchers; Sabine L van Elsland; Martien W Borgdorff; Joep M A Lange; Jan van den Hombergh
State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control.
Joep M A Lange; Bernhard Schwartländer
Introduction 15 million on ART by 2015: a realistic target or just a dream.
Sabine M Hermans; Andy I M Hoepelman; Catherine Katabira; Joep M A Lange; Barbara Castelnuovo; Alex Coutinho; Peter Mbidde; Yukari C Manabe
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joep Lange (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Natalie V S Vinkeles Melchers; Sabine L van Elsland; Martien W Borgdorff; Joep M A Lange; Jan van den Hombergh
State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control.
PloS one 2013;8(1):e53644.
2013: Joep M A Lange; Bernhard Schwartländer
Introduction 15 million on ART by 2015: a realistic target or just a dream.
Current opinion in HIV and AIDS 2013;8(1):1-3.
2012: Sabine M Hermans; Andy I M Hoepelman; Catherine Katabira; Joep M A Lange; Barbara Castelnuovo; Alex Coutinho; Peter Mbidde; Yukari C Manabe
Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda.
Journal of acquired immune deficiency syndromes (1999) 2012;60(2):e29-35.
2012: Raph L Hamers; Cissy Kityo; Joep M A Lange; Tobias F Rinke de Wit; Peter Mugyenyi
Global threat from drug resistant HIV in sub-Saharan Africa.
BMJ (Clinical research ed.) 2012;344():e4159.
2012: Marleen E Hendriks; Wendy Janssens; Amos M Kahwa; Berber Kramer; Judith Lammers; Joep M A Lange; Sayoki G Mfinanga; Tobias F Rinke de Wit; Marijke T L Roos; Tanimola M Akande; Igna Bonfrer; Lizzy M Brewster; Ingrid H de Beer; Esegiel Gaeb; Peter Gatongi; Jacques van der Gaag; Gert Van Rooy; Ferdinand W N M Wit; Constance Schultsz
Hypertension in sub-Saharan Africa: cross-sectional surveys in four rural and urban communities.
PloS one 2012;7(3):e32638.
2012: Reshmie A Ramautarsing; Kiat Ruxrungtham; Jasper van der Lugt; Jiratchaya Wongsabut; David Burger; Meena Gorowara; Chuleeporn Khongpetch; Joep M A Lange; Praphan Phanuphak; Jintanat Ananworanich; Anchalee Avihingsanon
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.
Journal of acquired immune deficiency syndromes (1999) 2012;59(1):55-8.
2011: Joep M A Lange
"Test and treat": is it enough?
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2011;52(6):801-2.
2010: Ingrid M M Schellens; Katalin Pogany; Geertje H A Westerlaken; José A M Borghans; Frank Miedema; Irene G M van Valkengoed; Frank P Kroon; Joep M A Lange; Kees Brinkman; Jan M Prins; Debbie Van Baarle
Immunological analysis of treatment interruption after early highly active antiretroviral therapy.
Viral immunology 2010;23(6):609-18.
2010: Radjin Steingrover; Evian Fernandez Garcia; Irene G M van Valkengoed; Vincent Bekker; Daniela Bezemer; Frank P Kroon; Lukas R C Dekker; Maria Prins; Frank de Wolf; Joep M A Lange; Jan M Prins
Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection.
AIDS research and human retroviruses 2010;26(4):379-87.
2008: Radjin Steingrover; Katalyn Pogány; Evian Fernandez Garcia; Suzanne Jurriaans; Kees Brinkman; Hanneke Schuitemaker; Frank Miedema; Joep M A Lange; Jan M Prins
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
AIDS (London, England) 2008;22(13):1583-8.
2008: Joep M A Lange; Onno P Schellekens; Marianne Lindner; Jacques van der Gaag
Public-private partnerships and new models of healthcare access.
Current opinion in HIV and AIDS 2008;3(4):509-13.
2008: Ferdinand W N M Wit; Anouk M Kesselring; Luuk Gras; Clemens Richter; Marchina E Van Der Ende; Kees Brinkman; Joep M A Lange; Frank de Wolf; Peter Reiss
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(6):933-40.
2007: Joost N Vermeulen; Jan M Prins; Evelien Bunnik; C Erik Hack; Suzanne Jurriaans; Frank Miedema; Joep M A Lange; Hanneke Schuitemaker
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals.
AIDS research and human retroviruses 2007;23(11):1348-53.
2007: Selwyn H Lowe; Elisabeth van Leeuwen; Jacqueline A H Droste; Fulco van der Veen; Peter Reiss; Joep M A Lange; David Burger; Sjoerd Repping; Jan M Prins
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
Therapeutic drug monitoring 2007;29(5):566-70.
2007: Selwyn H Lowe; Elly A M Hassink; Berthe L F van Eck-Smit; Jan C C Borleffs; Joep M A Lange; Peter Reiss
Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
HIV clinical trials 2007;8(5):337-44.
2007: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Duanghathai Sutthichom; Elly Kimenai; Elly A M Hassink; Andrew Hill; David A Cooper; Praphan Phanuphak; Joep M A Lange; David Burger; Kiat Ruxrungtham
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.
AIDS (London, England) 2007;21(12):1535-9.
2007: Raaj R Sankatsing; Ferdinand W N M Wit; Nadine Pakker; Joseph Vyankandondera; Francis Mmiro; Pius Okong; John J Kastelein; Joep M A Lange; Erik S G Stroes; Peter Reiss
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
The Journal of infectious diseases 2007;196(1):15-22.
2007: Luuk Gras; Anouk M Kesselring; James T Griffin; Ard I van Sighem; Christophe Fraser; Azra C Ghani; Frank Miedema; Peter Reiss; Joep M A Lange; Frank de Wolf
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):183-92.
2007: Saskia M E Vrouenraets; Ferdinand W N M Wit; Jacqueline van Tongeren; Joep M A Lange
Efavirenz: a review.
Expert opinion on pharmacotherapy 2007;8(6):851-71.
2007: Katalin Pogány; Irene G M van Valkengoed; Irene G Vanvalkengoed; Jan M Prins; Pythia T Nieuwkerk; Ineke van der Ende; Robbert H Kauffmann; Frank P Kroon; Annelies Verbon; Marianne F Nievaard; Joep M A Lange; Kees Brinkman
Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).
Journal of acquired immune deficiency syndromes (1999) 2007;44(4):395-400.
2007: Stephen J Kerr; Chris Duncombe; Anchalee Avihingsanon; Jintanat Ananworanich; Mark Boyd; Bunruan Sopa; B Medtech; Theshinee Chuenyam; David A Cooper; Joep M A Lange; Praphan Phanuphak; Kiat Ruxrungtham
Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2007;6(1):36-46.
2007: Henriëtte J Scherpbier; Vincent Bekker; Dasja Pajkrt; Suzanne Jurriaans; Joep M A Lange; Taco W Kuijpers
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Pediatrics 2007;119(3):e705-15.
2007: Papa Salif Sow; Leander F Otieno; Emmanuel Bissagnene; Cissy Kityo; Ruurd Bennink; Philippe Clevenbergh; Ferdinand W N M Wit; Esther Waalberg; Tobias F Rinke de Wit; Joep M A Lange
Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
Journal of acquired immune deficiency syndromes (1999) 2007;44(3):262-7.
2007: Frank van Leth; Ferdinand W N M Wit; Joep M A Lange
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response.
BMC medical research methodology 2007;7():14.
2007: Sanjay U C Sankatsing; Marion Cornelissen; Nico Kloosterboer; Kristel M L Crommentuyn; Tessa M Bosch; Frederik P Mul; Suzanne Jurriaans; Alwin D R Huitema; Jos H Beijnen; Joep M A Lange; Jan M Prins; Hanneke Schuitemaker
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
AIDS research and human retroviruses 2007;23(1):19-27.
2006: Selwyn H Lowe; Jori Symons; Jacqueline A H Droste; Reinier W Ten Kate; Suzanne Jurriaans; David Burger; Jan C C Borleffs; Joep M A Lange; Jan M Prins
No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.
HIV clinical trials 2006;7(6):285-90.
2006: Inge Derdelinckx; Mark A Wainberg; Joep M A Lange; Andrew Hill; Yasmin Halima; Charles A B Boucher
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.
PLoS medicine 2006;3(11):e454.
2006: Mark A Boyd; Narendra M Dixit; Umaporn Siangphoe; Neil E Buss; Miklos Salgo; Joep M A Lange; Praphan Phanuphak; David A Cooper; Alan S Perelson; Kiat Ruxrungtham
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
The Journal of infectious diseases 2006;194(9):1319-22.
2006: Philippe Clevenbergh; Stefaan Van der Borght; K van Cranenburgh; V Janssens; C Kitenge Lubangi; L Gahimbaza; Joep M A Lange; Tobias F Rinke de Wit; H Rijckborst
Database-supported teleconferencing: an additional clinical mentoring tool to assist a multinational company HIV/AIDS treatment program in Africa.
HIV clinical trials 2006;7(5):255-62.
2006: Frank van Leth; David B Hall; Joep M A Lange; Peter Reiss
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
HIV medicine 2006;7(6):347-50.
2006: Mark A Boyd; Andrew Carr; Kiat Ruxrungtham; Preeyaporn Srasuebkul; Darl Bien; Matthew Law; Somjai Wangsuphachart; Anchali Krisanachinda; Sakalaya Lerdlum; Joep M A Lange; Praphan Phanuphak; David A Cooper; Peter Reiss
Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.
The Journal of infectious diseases 2006;194(5):642-50.
2006: Stefaan Van der Borght; Tobias F Rinke de Wit; Vincent Janssens; Maarten Schim van der Loeff; Henk Rijckborst; Joep M A Lange
HAART for the HIV-infected employees of large companies in Africa.
Lancet 2006;368(9534):547-50.
2006: Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Peter Reiss; Apicha Mahanontharit; Joep M A Lange; Praphan Phanuphak; David A Cooper; David Burger
The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.
The Journal of antimicrobial chemotherapy 2006;57(6):1161-7.
2006: Mark A Boyd; Preeyaporn Srasuebkul; Kiat Ruxrungtham; Peter I Mackenzie; Verawan Uchaipichat; Michael Stek; Joep M A Lange; Praphan Phanuphak; David A Cooper; Wandee Udomuksorn; John O Miners
Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
Pharmacogenetics and genomics 2006;16(5):321-9.
2006: F Van Leth; Bregt S Kappelhoff; D Johnson; Marcelo H Losso; Anna Boron-Kaczmarska; M S Saag; J-M Livrozet; David B Hall; J Leith; Alwin D R Huitema; Ferdinand W N M Wit; Jos H Beijnen; Joep M A Lange
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
AIDS research and human retroviruses 2006;22(3):232-9.
2006: Henriëtte J Scherpbier; Vincent Bekker; Frank van Leth; Suzanne Jurriaans; Joep M A Lange; Taco W Kuijpers
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Pediatrics 2006;117(3):e528-36.
2006: Vincent Bekker; Henriëtte J Scherpbier; Radjin Steingrover; Suzanne Jurriaans; Joep M A Lange; Katja C Wolthers; Taco W Kuijpers
Viral dynamics after starting first-line HAART in HIV-1-infected children.
AIDS (London, England) 2006;20(4):517-23.
2006: Christine A Jansen; Erwan Piriou; Iris M De Cuyper; Karel van Dort; Joep M A Lange; Frank Miedema; Debbie Van Baarle
Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.
Antiviral therapy 2006;11(1):105-16.
2005: Nienke Vrisekoop; Sanjay U C Sankatsing; Christine A Jansen; Marijke Th L Roos; Sigrid A Otto; Hanneke Schuitemaker; Joep M A Lange; Jan M Prins; Frank Miedema
Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients.
AIDS research and human retroviruses 2005;21(12):991-6.
2005: Miriam Casula; Gerrit Jan Weverling; Ferdinand W N M Wit; Eveline C Timmermans; Michael Stek; Joep M A Lange; Peter Reiss
Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy.
The Journal of infectious diseases 2005;192(10):1794-800.
2005: Valériane Leroy; charlotte sakarovitch; Mario Cortina Borja; James McIntyre; Hoosen Coovadia; François Dabis; Marie-Louise Newell; J Saba; Glenda Gray; Ch Ndugwa; Ch Kilewo; Augustine Massawe; Praxedes Kituuka; Pius Okong; A Grulich; H von Briesen; J Goudsmit; Gunnel Biberfeld; Geert Haverkamp; Gerrit Jan Weverling; Joep M A Lange
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?
AIDS (London, England) 2005;19(16):1865-75.
2005: K Pogány; Hans L Zaaijer; Jan M Prins; Ferdinand W N M Wit; Joep M A Lange; Marcel G H M Beld
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.
AIDS research and human retroviruses 2005;21(11):922-6.
2005: Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Chris Duncombe; Michael Stek; Joep M A Lange; David A Cooper; Praphan Phanuphak
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
HIV medicine 2005;6(6):410-20.
2005: Reshma Saskia Autar; Marta Boffito; Elly A M Hassink; Ferdinand W N M Wit; Jintanat Ananworanich; Umaporn Siangphoe; Anton Pozniak; David A Cooper; Praphan Phanuphak; Joep M A Lange; Kiat Ruxrungtham; David Burger
Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
The Journal of antimicrobial chemotherapy 2005;56(5):908-13.
2005: Frank van Leth; Jan M Prins; Joep M A Lange; Suzanne E Geerlings
Protease inhibitors and non-nucleoside reverse transcriptase inhibitors have a comparable effect on the CD4 cell change after switching to tenofovir-based regimens.
AIDS (London, England) 2005;19(15):1722-3.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Joep M A Lange; Jos H Beijnen
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV clinical trials 2005;6(5):254-61.
2005: Selwyn H Lowe; Jori Symons; Elly A M Hassink; Reinier W Ten Kate; Clemens Richter; G Schreij; Peter P Koopmans; Job R Juttmann; I van der Tweel; Joep M A Lange; Jan C C Borleffs
Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
HIV clinical trials 2005;6(5):235-45.
2005: Joep M A Lange
We must not let protestors derail trials of pre-exposure prophylaxis for HIV.
PLoS medicine 2005;2(9):e248.
2005: Erwan Piriou; Christine A Jansen; Karel van Dort; Iris M De Cuyper; Nening M Nanlohy; Joep M A Lange; Marinus H J van Oers; Frank Miedema; Debbie Van Baarle
Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(3):2010-7.
2005: Christine A Jansen; Iris M De Cuyper; Radjin Steingrover; Suzanne Jurriaans; Sanjay U C Sankatsing; Jan M Prins; Joep M A Lange; Debbie Van Baarle; Frank Miedema
Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.
AIDS (London, England) 2005;19(11):1145-54.
2005: Vincent Bekker; Corine Bronke; Henriëtte J Scherpbier; Jan F L Weel; Suzanne Jurriaans; Pauline M E Wertheim-van Dillen; Frank van Leth; Joep M A Lange; kiki tesselaar; Debbie Van Baarle; Taco W Kuijpers
Cytomegalovirus rather than HIV triggers the outgrowth of effector CD8+CD45RA+CD27- T cells in HIV-1-infected children.
AIDS (London, England) 2005;19(10):1025-34.
2005: Frank van Leth; S Andrews; B Grinsztejn; E Wilkins; M K Lazanas; Joep M A Lange; J Montaner
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
AIDS (London, England) 2005;19(5):463-71.
2005: Frank van Leth; Casper B Huisamen; Roberto Badaro; Bernard Vandercam; Joss de Wet; Julio S G Montaner; David B Hall; Ferdinand W N M Wit; Joep M A Lange
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):296-300.
2005: Akke K van der Bij; Nico Kloosterboer; Maria Prins; Brigitte Boeser-Nunnink; Ronald B Geskus; Joep M A Lange; Roel A Coutinho; Hanneke Schuitemaker
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study.
The Journal of infectious diseases 2005;191(5):678-85.
2005: Chris Duncombe; Stephen J Kerr; Kiat Ruxrungtham; Gregory J Dore; Matthew G Law; Sean Emery; Joep M A Lange; Praphan Phanuphak; David A Cooper
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting.
AIDS (London, England) 2005;19(2):169-78.
2005: Reshma Saskia Autar; Ferdinand W N M Wit; Jongkol sankote; Apicha Mahanontharit; Thanomsak Anekthananon; Piroon Mootsikapun; Khanjtta Sujaikaew; David A Cooper; Joep M A Lange; Praphan Phanuphak; Kiat Ruxrungtham; David Burger
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Antiviral therapy 2005;10(8):937-43.
2005: Bregt S Kappelhoff; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Ezio Baraldi; Francesco Montella; David E Uip; Melanie A Thompson; Darren B Russell; Joep M A Lange; Jos H Beijnen; Alwin D R Huitema
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antiviral therapy 2005;10(4):489-98.
2004: Selwyn H Lowe; Jan M Prins; Joep M A Lange
Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome.
The Netherlands journal of medicine 2004;62(11):424-40.
2004: Mette D Hazenberg; Sigrid A Otto; Annemarie M C van Rossum; Henriëtte J Scherpbier; Ronald de Groot; Taco W Kuijpers; Joep M A Lange; Dörte Hamann; Rob J De Boer; José A M Borghans; Frank Miedema
Establishment of the CD4+ T-cell pool in healthy children and untreated children infected with HIV-1.
Blood 2004;104(12):3513-9.
2004: Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M A Lange; Min Lu; Ben Berkhout
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
Journal of virology 2004;78(22):12428-37.
2004: Kelly Safreed-Harmon; David A Cooper; Joep M A Lange; Chris Duncombe; Praphan Phanuphak
The HIV Netherlands Australia Thailand research collaboration: lessons from 7 years of clinical research.
AIDS (London, England) 2004;18(15):1971-8.
2004: Frank van Leth; Brian Conway; Hector Laplumé; Des Martin; Martin Fisher; Ante Jelaska; Ferdinand W N M Wit; Joep M A Lange
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
Antiviral therapy 2004;9(5):721-8.
2004: Frank van Leth; Praphan Phanuphak; Erik S G Stroes; Brian Gazzard; Pedro Cahn; François Raffi; Robin Wood; Mark Bloch; Christine Katlama; John J P Kastelein; Mauro Schechter; Robert L Murphy; Andrzej Horban; David B Hall; Joep M A Lange; Peter Reiss
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
PLoS medicine 2004;1(1):e19.
2004: Sanjay U C Sankatsing; Suzanne Jurriaans; Peter van Swieten; Frank van Leth; Marion Cornelissen; Frank Miedema; Joep M A Lange; Hanneke Schuitemaker; Jan M Prins
Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients.
AIDS (London, England) 2004;18(14):1925-31.
2004: Jeannine F J B Nellen; Igor Schillevoort; Ferdinand W N M Wit; Alina S Bergshoeff; Mieke H Godfried; Kees Boer; Joep M A Lange; David Burger; Jan M Prins
Nelfinavir plasma concentrations are low during pregnancy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(5):736-40.
2004: Jeannine F J B Nellen; Ferdinand W N M Wit; Frank de Wolf; Suzanne Jurriaans; Joep M A Lange; Jan M Prins
Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.
Journal of acquired immune deficiency syndromes (1999) 2004;36(4):943-50.
2004: Helene Gayle; Joep M A Lange
Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention.
Lancet 2004;364(9428):6-8.
2004: Selwyn H Lowe; Sanjay U C Sankatsing; Sjoerd Repping; Fulco van der Veen; Peter Reiss; Joep M A Lange; Jan M Prins
Is the male genital tract really a sanctuary site for HIV? Arguments that it is not.
AIDS (London, England) 2004;18(10):1353-62.
2004: Marc van der Valk; Gideon Allick; Gerrit Jan Weverling; Johannes A Romijn; Mariëtte T Ackermans; Joep M A Lange; Berthe L F van Eck-Smit; Cornelis van Kuijk; Erik Endert; Hans P Sauerwein; Peter Reiss
Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients.
The Journal of clinical endocrinology and metabolism 2004;89(7):3554-60.
2004: David A Cooper; Joep M A Lange
Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
The Lancet infectious diseases 2004;4(7):426-36.
2004: Joep M A Lange; Vallop Thaineua
Access for all?
Science (New York, N.Y.) 2004;304(5679):1875.
2004: Joep M A Lange; Jos Perriens; Daniel R Kuritzkes; Debrework Zewdie
What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection.
AIDS (London, England) 2004;18 Suppl 3():S69-74.
2004: Chaiwat Ungsedhapand; Preeyaporn Srasuebkul; Peter Cardiello; Kiat Ruxrungtham; Winai Ratanasuwan; Eugene D M B Kroon; Metta Tongtalung; Nittaya Juengprasert; Sasiwimol Ubolyam; Umaporn Siangphoe; Sean Emery; Joep M A Lange; David A Cooper; Praphan Phanuphak
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):693-701.
2004: W. Phillip Law; Chris Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper; Gregory J Dore
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
AIDS (London, England) 2004;18(8):1169-77.
2004: Frank van Leth; Praphan Phanuphak; Kiat Ruxrungtham; Ezio Baraldi; S Miller; B Gazzard; Pedro Cahn; U G Lalloo; I P van der Westhuizen; D R Malan; M A Johnson; B R Santos; F Mulcahy; Robin Wood; G C Levi; G Reboredo; Kathleen E Squires; Isabel Cassetti; D Petit; F Raffi; Christine Katlama; Robert L Murphy; Andrzej Horban; J P Dam; Elly A M Hassink; Remko van Leeuwen; P Robinson; Ferdinand W N M Wit; Joep M A Lange
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Lancet 2004;363(9417):1253-63.
2004: Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Antimicrobial agents and chemotherapy 2004;48(4):1073-81.
2004: Daniel H Blanckenberg; Robin Wood; Andrzej Horban; Marek Beniowski; Anna Boron-Kaczmarska; Hanna Trocha; Waldemar Halota; Reinhold E Schmidt; G Fatkenheuer; Heiko Jessen; Joep M A Lange
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
AIDS (London, England) 2004;18(4):631-40.
2004: Frank van Leth; Ferdinand W N M Wit; Peter Reiss; J K M E Schattenkerk; Marchina E Van Der Ende; M M E Schneider; Jan W Mulder; P H J Frissen; Frank de Wolf; Joep M A Lange
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
HIV medicine 2004;5(2):74-81.
2004: Sanjay U C Sankatsing; Patrick G Hoggard; Alwin D R Huitema; Rolf W Sparidans; Stephen Kewn; Kristel M L Crommentuyn; Joep M A Lange; Jos H Beijnen; David J Back; Jan M Prins
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Clinical pharmacokinetics 2004;43(12):823-32.
2004: Peter Reiss; Miriam Casula; Anthony de Ronde; Gerrit Jan Weverling; Jaap Goudsmit; Joep M A Lange
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
HIV medicine 2004;5(1):11-4.
2003: Sanjay U C Sankatsing; Gerrit Jan Weverling; Monika Peeters; Gerben van't Klooster; Boris Gruzdev; Aza Rakhmanova; Sven A Danner; Suzanne Jurriaans; Jan M Prins; Joep M A Lange
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
AIDS (London, England) 2003;17(18):2623-7.
2003: Ard I van Sighem; Mark A van de Wiel; Azra C Ghani; Marielle Jambroes; Peter Reiss; Inge C Gyssens; Kees Brinkman; Joep M A Lange; Frank de Wolf
Mortality and progression to AIDS after starting highly active antiretroviral therapy.
AIDS (London, England) 2003;17(15):2227-36.
2003: W. Phillip Law; Gregory J Dore; Chris Duncombe; Apicha Mahanontharit; Mark A Boyd; Kiat Ruxrungtham; Joep M A Lange; Praphan Phanuphak; David A Cooper
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
AIDS (London, England) 2003;17(15):2191-9.
2003: Mark A Boyd; Rob E Aarnoutse; Kiat Ruxrungtham; Michael Stek; Rolf P G van Heeswijk; Joep M A Lange; David A Cooper; Praphan Phanuphak; David Burger
Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):134-9.
2003: Frank van Leth; Joep M A Lange
Use of composite end points to measure clinical events.
JAMA : the journal of the American Medical Association 2003;290(11):1456-7; author reply 1457.
2003: Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Persistent immune activation in HIV-1 infection is associated with progression to AIDS.
AIDS (London, England) 2003;17(13):1881-8.
2003: Joep M A Lange
Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S40-52.
2003: Peter Cardiello; Tarika Samor; David Burger; Richard Hoetelmans; Apicha Mahanontharit; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: Remko van Leeuwen; Christine Katlama; Robert L Murphy; Kathleen E Squires; José M Gatell; Andrzej Horban; Bonaventura Clotet; Shlomo Staszewski; Arne van Eeden; Nathan Clumeck; Mauro Moroni; Andrew T Pavia; Reinhold E Schmidt; Juan Gonzalez-Lahoz; Julio Montaner; Francisco Antunes; Roy M Gulick; Dénes Bánhegyi; Marc van der Valk; Peter Reiss; Liesbeth van Weert; Frank van Leth; Victoria A Johnson; Jean-Pierre Sommadossi; Joep M A Lange
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
AIDS (London, England) 2003;17(7):987-99.
2003: Sanjay U C Sankatsing; Rieneke van Praag; Ronald P van Rij; Ronald Rientsma; Suzanne Jurriaans; Joep M A Lange; Jan M Prins; Hanneke Schuitemaker
Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
Antiviral therapy 2003;8(2):137-42.
2003: Cornelis H W Koks; Alwin D R Huitema; Eugene D M B Kroon; Theshinee Chuenyam; Rolf W Sparidans; Joep M A Lange; Jos H Beijnen
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Therapeutic drug monitoring 2003;25(2):229-33.
2003: Peter Cardiello; Tarkika Monhaphol; Apicha Mahanontharit; Rolf P G van Heeswijk; David Burger; Andrew Hill; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):375-9.
2003: Johannes A Bogaards; Gerrit Jan Weverling; Ronald B Geskus; Frank Miedema; Joep M A Lange; Patrick Bossuyt; Jaap Goudsmit
Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
Antiviral therapy 2003;8(1):43-50.
2003: David Burger; Patricia W H Hugen; Rob E Aarnoutse; Richard Hoetelmans; Marielle Jambroes; Pythia T Nieuwkerk; Gerrit Schreij; M M E Schneider; Marchina E Van Der Ende; Joep M A Lange
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(1):73-80.
2003: Bernhard Schwartländer; Joep M A Lange
Time to move on HIV/AIDS treatment and care.
IAPAC monthly 2003;9(1):6-7.
2002: Ferdinand W N M Wit; Ronald P van Rij; Gerrit Jan Weverling; Joep M A Lange; Hanneke Schuitemaker
CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.
The Journal of infectious diseases 2002;186(12):1726-32.
2002: Johan R Boelaert; Geneviève M Dom; Alwin D Huitema; Jos H Beijnen; Joep M A Lange
The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.
AIDS (London, England) 2002;16(16):2221-3.
2002: Sanjay U C Sankatsing; Jacqueline A H Droste; David Burger; Rieneke van Praag; Suzanne Jurriaans; Joep M A Lange; Jan M Prins
Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.
AIDS (London, England) 2002;16(12):1698-700.
2002: Joep M A Lange; Fransje W van der Waals
Prioritising access to antiretroviral therapy in resource-poor settings.
Journal of HIV therapy 2002;7(3):59-62.
2002: Rolf P G van Heeswijk; Henriëtte J Scherpbier; Linda A de Koning; Hugo S A Heymans; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Therapeutic drug monitoring 2002;24(4):487-91.
2002: Selwyn H Lowe; Jan M Prins; Johannes van der Lelie; Joep M A Lange
Does highly active antiretroviral therapy induce sickle cell crises?
AIDS (London, England) 2002;16(11):1572-4.
2002: Brian S N Blank; Pieter L Meenhorst; W Pauw; Jan W Mulder; WC van Dijk; Paul H M Smits; F Roeles; Jaap Middeldorp; Joep M A Lange
Detection of late pp67-mRNA by NASBA in peripheral blood for the diagnosis of human cytomegalovirus disease in AIDS patients.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2002;25(1):29-38.
2002: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan F L Weel; Suzanne Jurriaans; Joep M A Lange
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
The Journal of infectious diseases 2002;186(1):23-31.
2002: Mette D Hazenberg; Sigrid A Otto; Ferdinand W N M Wit; Joep M A Lange; Dörte Hamann; Frank Miedema
Discordant responses during antiretroviral therapy: role of immune activation and T cell redistribution rather than true CD4 T cell loss.
AIDS (London, England) 2002;16(9):1287-9.
2002: Jeanne P Dieleman; Miriam C J M Sturkenboom; Ferdinand W N M Wit; Marielle Jambroes; Jan W Mulder; Jacob H Ten Veen; Job Juttmann; Bruno H Ch Stricker; Joep M A Lange; Marchina E Van Der Ende
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
The Journal of infectious diseases 2002;185(9):1261-8.
2002: Peter Cardiello; Rolf P G van Heeswijk; Elly A M Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika Samor; Wassana Worarien; Jos H Beijnen; Richard Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M A Lange; Praphan Phanuphak
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Chokechai Rongkavilit; Rolf P G van Heeswijk; Sompop Limpongsanurak; Pimolrat Thaithumyanon; Chantana Boonrod; Elly A M Hassink; Aeumporn Srigritsanapol; Theshinee Chuenyam; Sasiwimol Ubolyam; Richard Hoetelmans; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):455-63.
2002: Joep M A Lange; Remko van Leeuwen
Antiretroviral therapy and resistance to antiretroviral drugs.
Ethiopian medical journal 2002;40 Suppl 1():51-75.
2002: Stefan Kostense; Sigrid A Otto; Gerlinde J Knol; Erik H Manting; Nening M Nanlohy; Christine Jansen; Joep M A Lange; Marinus H J van Oers; Frank Miedema; Debbie Van Baarle
Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
European journal of immunology 2002;32(4):1080-9.
2002: Jaap Goudsmit; Johannes A Bogaards; Suzanne Jurriaans; Hanneke Schuitemaker; Joep M A Lange; Roel A Coutinho; Gerrit Jan Weverling
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia.
AIDS (London, England) 2002;16(5):791-3.
2002: Jeanne P Dieleman; Marielle Jambroes; Inge C Gyssens; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Wilhelmina M C Mulder; Frank de Wolf; Gerrit Jan Weverling; Joep M A Lange; Peter Reiss; Kees Brinkman
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort.
AIDS (London, England) 2002;16(5):737-45.
2002: Rieneke van Praag; Ferdinand W N M Wit; Suzanne Jurriaans; Frank de Wolf; Jan M Prins; Joep M A Lange
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
AIDS (London, England) 2002;16(5):719-25.
2002: Ronald P van Rij; Rieneke van Praag; Jan M Prins; Ronald Rientsma; Suzanne Jurriaans; Joep M A Lange; Hanneke Schuitemaker
Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen.
Antiviral therapy 2002;7(1):37-41.
2002: Ronald P van Rij; Janny A Visser; Rieneke van Praag; Ronald Rientsma; Jan M Prins; Joep M A Lange; Hanneke Schuitemaker
Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.
Journal of virology 2002;76(6):3054-8.
2002: Rieneke van Praag; Elisabeth C M van Weert; Rolf P G van Heeswijk; Xiao-Jian Zhou; Jean-Pierre Sommadossi; Suzanne Jurriaans; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.
Antimicrobial agents and chemotherapy 2002;46(3):896-9.
2001: Ferdinand W N M Wit; Robin Wood; Andrzej Horban; Marek Beniowski; Reinhold E Schmidt; Glenda Gray; Adriano Lazzarin; A Lafeuillade; D Paes; Hilde Carlier; L van Weert; C de Vries; Remko van Leeuwen; Joep M A Lange
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
AIDS (London, England) 2001;15(18):2423-9.
2001: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
Antiviral therapy 2001;6(4):201-29.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Richard Hoetelmans; Joep M A Lange; Jos H Beijnen
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(6):606-11.
2001: Chokechai Rongkavilit; Pimolrat Thaithumyanon; Theshinee Chuenyam; B D Damle; Sompop Limpongsanurak; C Boonrod; A Srigritsanapol; Elly A M Hassink; Richard Hoetelmans; David A Cooper; Joep M A Lange; Kiat Ruxrungtham; Praphan Phanuphak
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Antimicrobial agents and chemotherapy 2001;45(12):3585-90.
2001: Jaap Goudsmit; Gerrit Jan Weverling; Lia van der Hoek; Anthony de Ronde; Frank Miedema; Roel A Coutinho; Joep M A Lange; Maarten C Boerlijst
Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains.
AIDS (London, England) 2001;15(17):2293-301.
2001: Annemarie M C van Rossum; Henriëtte J Scherpbier; Ellen G van Lochem; Nadine Pakker; WA Slieker; Katja C Wolthers; Marijke Th L Roos; J H Kuijpers; Herbert Hooijkaas; Nico G Hartwig; S P M Geelen; Tom F W Wolfs; Joep M A Lange; Frank Miedema; Ronald de Groot
Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.
AIDS (London, England) 2001;15(17):2267-75.
2001: Marc van der Valk; Peter H Bisschop; Johannes A Romijn; Mariëtte T Ackermans; Joep M A Lange; Erik Endert; Peter Reiss; Hans P Sauerwein
Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways.
AIDS (London, England) 2001;15(16):2093-100.
2001: Pythia T Nieuwkerk; EH Gisolf; MH Reijers; Joep M A Lange; Sven A Danner; Mirjam A G Sprangers
Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection.
AIDS (London, England) 2001;15(15):1985-91.
2001: Rieneke van Praag; Rolf P G van Heeswijk; Suzanne Jurriaans; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(8):e91-2.
2001: Rieneke van Praag; Sjoerd Repping; Jan W A de Vries; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
Antimicrobial agents and chemotherapy 2001;45(10):2902-7.
2001: Pythia T Nieuwkerk; Mirjam A G Sprangers; David Burger; Richard Hoetelmans; Patricia W H Hugen; Sven A Danner; Marchina E Van Der Ende; M M E Schneider; G Schrey; Pieter L Meenhorst; Herman Sprenger; Robbert H Kauffmann; Marielle Jambroes; Margaret A Chesney; Frank de Wolf; Joep M A Lange
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Archives of internal medicine 2001;161(16):1962-8.
2001: Marielle Jambroes; Gerrit Jan Weverling; Peter Reiss; Sven A Danner; Suzanne Jurriaans; Jacob H Ten Veen; Marchina E Van Der Ende; Martin Schutten; M M E Schneider; R Schuurman; Jan W Mulder; A C Kroes; Joep M A Lange; Frank de Wolf
[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Nederlands tijdschrift voor geneeskunde 2001;145(33):1591-7.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Gerrit Schreij; Siebe van der Geest; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):344-9.
2001: Agnes I Veldkamp; M Harris; J S Montaner; G Moyle; B Gazzard; M Youle; M Johnson; MO Kwakkelstein; Hilde Carlier; Remko van Leeuwen; Jos H Beijnen; Joep M A Lange; Peter Reiss; Richard Hoetelmans
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 2001;184(1):37-42.
2001: Stefan Kostense; Frank M Raaphorst; Jeanine Joling; Daan W Notermans; Jan M Prins; Sven A Danner; Peter Reiss; Joep M A Lange; Judy M Teale; Frank Miedema
T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy.
AIDS (London, England) 2001;15(9):1097-107.
2001: Agnes I Veldkamp; Gerrit Jan Weverling; Joep M A Lange; J S Montaner; Peter Reiss; D A Cooper; STEFANO VELLA; D Hall; Jos H Beijnen; Richard Hoetelmans
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Chaiwat Ungsedhapand; Eugene D M B Kroon; Surapol Suwanagool; Kiat Ruxrungtham; N Yimsuan; Areeaue Sonjai; Sasiwimol Ubolyam; Supranee Buranapraditkun; Surapee Tiengrim; Nadine Pakker; Chaiyos Kunanusont; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Journal of acquired immune deficiency syndromes (1999) 2001;27(2):116-23.
2001: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; J H Beijnen; Joep M A Lange; Richard Hoetelmans
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(3):255-8.
2001: Rieneke van Praag; Jan M Prins; Marijke Th L Roos; P T A Schellekens; Ineke J M ten Berge; Si-La Yong; Hanneke Schuitemaker; A J Eerenberg; Suzanne Jurriaans; Frank de Wolf; C H Fox; Jaap Goudsmit; F Miedema; Joep M A Lange
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
Journal of clinical immunology 2001;21(3):218-26.
2001: Roelien H Enting; Jan M Prins; Suzanne Jurriaans; K Brinkman; Peter Portegies; Joep M A Lange
Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;32(7):1095-9.
2001: NA Foudraine; Suzanne Jurriaans; Gerrit Jan Weverling; David Burger; Richard Hoetelmans; Marijke Th L Roos; JJ Maas; Frank Miedema; Peter Reiss; Peter Portegies; Frank de Wolf; Joep M A Lange
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Antiviral therapy 2001;6(1):55-62.
2001: David Burger; Patricia W H Hugen; Rob E Aarnoutse; Jeanne P Dieleman; J M Prins; T van der Poll; Jacob H Ten Veen; Jan W Mulder; Pieter L Meenhorst; Willem L Blok; J T van der Meer; Peter Reiss; Joep M A Lange
A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.
Journal of acquired immune deficiency syndromes (1999) 2001;26(3):218-24.
2001: MH Reijers; Gerrit Jan Weverling; Suzanne Jurriaans; Marijke Th L Roos; Ferdinand W N M Wit; Hugo M Weigel; Reinier W Ten Kate; Jan W Mulder; Clemens Richter; Hadewych J M ter Hofstede; Herman Sprenger; Richard Hoetelmans; Hanneke Schuitemaker; Joep M A Lange
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
AIDS (London, England) 2001;15(1):129-31.
2000: M den Brinker; Ferdinand W N M Wit; Pauline M E Wertheim-van Dillen; Suzanne Jurriaans; Jan F L Weel; Remko van Leeuwen; Nadine Pakker; Peter Reiss; Sven A Danner; Gerrit Jan Weverling; Joep M A Lange
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
AIDS (London, England) 2000;14(18):2895-902.
2000: H Putter; Jan M Prins; Suzanne Jurriaans; M Roos; N M Ferguson; Rieneke van Praag; Lia van der Hoek; Hanneke Schuitemaker; R M Anderson; Jaap Goudsmit; Joep M A Lange; Frank de Wolf
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection.
AIDS (London, England) 2000;14(18):2831-9.
2000: EH Gisolf; Rieneke van Praag; Suzanne Jurriaans; Peter Portegies; Jaap Goudsmit; Sven A Danner; Joep M A Lange; Jan M Prins
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2000;25(5):426-33.
2000: David Burger; Patricia W H Hugen; Marchina E Van Der Ende; P van Wijngaarden; Rob E Aarnoutse; Peter Reiss; Joep M A Lange
Once-daily indinavir plus ritonavir: preliminary results of the PIPO study.
AIDS (London, England) 2000;14(16):2621-3.
2000: Patricia W H Hugen; David Burger; Hadewych J M ter Hofstede; Peter P Koopmans; Michael Stek; Yechiel A Hekster; Peter Reiss; Joep M A Lange
Dose-finding study of a once-daily indinavir/ritonavir regimen.
Journal of acquired immune deficiency syndromes (1999) 2000;25(3):236-45.
2000: Daan W Notermans; Frank de Wolf; P Oudshoorn; H T Cuijpers; M Pirillo; F W Tiller; D R McClernon; Jan M Prins; Joep M A Lange; Sven A Danner; Jaap Goudsmit; Suzanne Jurriaans
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.
AIDS research and human retroviruses 2000;16(15):1507-17.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Peter Reiss; Joep M A Lange; MO Kwakkelstein; Jos H Beijnen; Richard Hoetelmans
Nevirapine plus didanosine: once or twice daily combination?
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):93-5.
2000: Mette D Hazenberg; Sigrid A Otto; James W T Cohen Stuart; M C Verschuren; Jan C C Borleffs; Charles A B Boucher; Roel A Coutinho; Joep M A Lange; Tobias F Rinke de Wit; Aster Tsegaye; Jacques J M van Dongen; Dörte Hamann; Rob J De Boer; Frank Miedema
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection.
Nature medicine 2000;6(9):1036-42.
2000: Pythia T Nieuwkerk; MH Reijers; Hugo M Weigel; Joep M A Lange; M A Sprangers
Quality of life in maintenance vs prolonged induction therapy for HIV.
JAMA : the journal of the American Medical Association 2000;284(2):178-9.
2000: Kiat Ruxrungtham; Eugene D M B Kroon; Chaiwat Ungsedhapand; Somsong Teeratakulpisarn; Sasiwimol Ubolyam; Supranee Buranapraditkun; R van Leeuwen; Gerrit Jan Weverling; Chaiyos Kunanusont; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients.
AIDS (London, England) 2000;14(10):1375-82.
2000: Eugene D M B Kroon; Chaiwat Ungsedhapand; Kiat Ruxrungtham; M Chuenyam; Sasiwimol Ubolyam; M E Newell; R van Leeuwen; Chaiyos Kunanusont; S Buranapraditkul; Sunee Sirivichayakul; Joep M A Lange; David A Cooper; Praphan Phanuphak
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration.
AIDS (London, England) 2000;14(10):1349-56.
2000: DR Clark; S Repping; Nadine Pakker; J M Prins; Daan W Notermans; Ferdinand W N M Wit; Peter Reiss; S A Danner; R A Coutinho; Joep M A Lange; Frank Miedema
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy.
Blood 2000;96(1):242-9.
2000: Rieneke van Praag; Gerrit Jan Weverling; Peter Portegies; Suzanne Jurriaans; X J Zhou; M L Turner-Foisy; Jean-Pierre Sommadossi; David Burger; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS (London, England) 2000;14(9):1187-94.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
AIDS (London, England) 2000;14(9):F103-10.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Joep M A Lange; Sven A Danner; NA Foudraine; MO Kwakkelstein; Peter Reiss; Jos H Beijnen; Richard Hoetelmans
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
AIDS (London, England) 2000;14(8):F77-82.
2000: Brian S N Blank; Pieter L Meenhorst; Jan W Mulder; Gerrit Jan Weverling; H Putter; W Pauw; WC van Dijk; P Smits; S Lie-A-Ling; P Reiss; Joep M A Lange
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients.
Journal of clinical microbiology 2000;38(2):563-9.
2000: Roelien H Enting; NA Foudraine; Joep M A Lange; Suzanne Jurriaans; Tom van der Poll; Gerrit Jan Weverling; Peter Portegies
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
Journal of neuroimmunology 2000;102(2):216-21.
2000: MH Reijers; Hugo M Weigel; A A Hart; Reinier W Ten Kate; Jan W Mulder; Peter Reiss; Hanneke Schuitemaker; Richard Hoetelmans; Gerrit Jan Weverling; Joep M A Lange
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
AIDS (London, England) 2000;14(1):59-67.
1999: Brian S N Blank; Pieter L Meenhorst; Gerrit Jan Weverling; A A Stout-Zonneveld; W Pauw; Jan W Mulder; WC van Dijk; P Smits; Joep M A Lange
Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients.
AIDS (London, England) 1999;13(18):2533-9.
1999: Jan M Prins; Suzanne Jurriaans; Rieneke van Praag; H Blaak; Ronald P van Rij; P T A Schellekens; Ineke J M ten Berge; Si-La Yong; C H Fox; Marijke Th L Roos; Frank de Wolf; Jaap Goudsmit; Hanneke Schuitemaker; Joep M A Lange
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy.
AIDS (London, England) 1999;13(17):2405-10.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(1):55-61.
1999: Rolf P G van Heeswijk; Agnes I Veldkamp; Richard Hoetelmans; Jan W Mulder; Gerrit Schreij; A Hsu; Joep M A Lange; Jos H Beijnen; Pieter L Meenhorst
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
AIDS (London, England) 1999;13(14):F95-9.
1999: Ronald P van Rij; Peter Portegies; T Hallaby; Joep M A Lange; J Visser; Ana Maria de Roda Husman; Angélique B van 't Wout; Hanneke Schuitemaker
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex.
The Journal of infectious diseases 1999;180(3):854-7.
1999: Oscar Pontesilli; SR Kerkhof-Garde; Daan W Notermans; NA Foudraine; Marijke Th L Roos; Michel Klein; Sven A Danner; Joep M A Lange; Frank Miedema
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
The Journal of infectious diseases 1999;180(1):76-86.
1999: K Brinkman; J M Prins; Suzanne Jurriaans; Joep M A Lange
[Primary HIV-infection: infectious mononucleosis-like presentation with treatment options].
Nederlands tijdschrift voor geneeskunde 1999;143(22):1129-33.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):151-7.
1999: Ferdinand W N M Wit; Remko van Leeuwen; Gerrit Jan Weverling; Suzanne Jurriaans; K Nauta; Radjin Steingrover; J Schuijtemaker; X Eyssen; D Fortuin; M Weeda; Frank de Wolf; Peter Reiss; Sven A Danner; Joep M A Lange
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 1999;179(4):790-8.
1999: Nadine Pakker; E D Kroon; Marijke Th L Roos; Sigrid A Otto; D Hall; Ferdinand W N M Wit; Dörte Hamann; Marchina E Van Der Ende; Frans A Claessen; Robbert H Kauffmann; Peter P Koopmans; Frank P Kroon; C H ten Napel; Herman Sprenger; Hugo M Weigel; Julio S G Montaner; Joep M A Lange; Peter Reiss; P T A Schellekens; Frank Miedema
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
AIDS (London, England) 1999;13(2):203-12.
1999: NA Foudraine; Egbert Hovenkamp; Daan W Notermans; Pieter L Meenhorst; Michel Klein; Joep M A Lange; Frank Miedema; Peter Reiss
Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients.
AIDS (London, England) 1999;13(2):177-84.
1999: M Koot; Remko van Leeuwen; R E de Goede; IP Keet; S Danner; J K Eeftinck Schattenkerk; Peter Reiss; M Tersmette; Joep M A Lange; Hanneke Schuitemaker
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.
The Journal of infectious diseases 1999;179(1):254-8.
1998: Jeanne P Dieleman; M E Hillebrand-Haverkort; Marchina E Van Der Ende; Miriam C J M Sturkenboom; Joep M A Lange; Bruno H Ch Stricker
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Nederlands tijdschrift voor geneeskunde 1998;142(52):2856-60.
1998: Neil Renwick; T Halaby; Gerrit Jan Weverling; Nicole Dukers; Guy R Simpson; Roel A Coutinho; Joep M A Lange; Thomas F Schulz; Jaap Goudsmit
Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
AIDS (London, England) 1998;12(18):2481-8.
1998: Richard Hoetelmans; Rolf P G van Heeswijk; M Profijt; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Peter Reiss; Jos H Beijnen
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
AIDS (London, England) 1998;12(17):F211-6.
1998: Rolf P G van Heeswijk; Richard Hoetelmans; Remko Harms; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):159-68.
1998: Roelien H Enting; Richard Hoetelmans; Joep M A Lange; David Burger; J H Beijnen; Peter Portegies
Antiretroviral drugs and the central nervous system.
AIDS (London, England) 1998;12(15):1941-55.
1998: MH Reijers; Gerrit Jan Weverling; Suzanne Jurriaans; Ferdinand W N M Wit; R van Leeuwen; Sylvia M Bruisten; P H J Frissen; Hugo M Weigel; Jan W Mulder; Reinier W Ten Kate; Frank de Wolf; Hanneke Schuitemaker; Joep M A Lange
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Nederlands tijdschrift voor geneeskunde 1998;142(40):2230.
1998: NA Foudraine; JJ de Jong; G Jan Weverling; Birgit H B van Benthem; JJ Maas; IP Keet; Suzanne Jurriaans; Marijke Th L Roos; K Vandermeulen; Frank de Wolf; Joep M A Lange
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
AIDS (London, England) 1998;12(12):1513-9.
1998: Gerrit Jan Weverling; Joep M A Lange; Suzanne Jurriaans; Jan M Prins; Vladimir V Lukashov; Daan W Notermans; M Roos; Hanneke Schuitemaker; Richard Hoetelmans; Sven A Danner; Jaap Goudsmit; Frank de Wolf
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
AIDS (London, England) 1998;12(11):F117-22.
1998: Richard Hoetelmans; MH Reijers; Gerrit Jan Weverling; Reinier W Ten Kate; Ferdinand W N M Wit; Jan W Mulder; Hugo M Weigel; P H J Frissen; M Roos; Suzanne Jurriaans; Hanneke Schuitemaker; Frank de Wolf; Jos H Beijnen; Joep M A Lange
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: MH Reijers; Gerrit Jan Weverling; S Jurriaans; Ferdinand W N M Wit; Hugo M Weigel; Reinier W Ten Kate; Jan W Mulder; P H J Frissen; R van Leeuwen; P Reiss; H Schuitemaker; Frank de Wolf; Joep M A Lange
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Lancet 1998;352(9123):185-90.
1998: NA Foudraine; Richard Hoetelmans; Joep M A Lange; Frank de Wolf; Birgit H B van Benthem; JJ Maas; IP Keet; Peter Portegies
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
Lancet 1998;351(9115):1547-51.
1998: Frank de Wolf; JJ de Jong; K Hertogs; Sven A Danner; Joep M A Lange; Jaap Goudsmit
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97].
Nederlands tijdschrift voor geneeskunde 1998;142(11):573-8.
1998: Joep M A Lange
Strategies for rescue therapy.
Antiviral therapy 1998;3 Suppl 4():75-7.
1998: Praphan Phanuphak; David A Cooper; Joep M A Lange
Clinical trials in Asia.
AIDS (London, England) 1998;12 Suppl B():S163-7.
1998: NA Foudraine; Gerrit Jan Weverling; T van Gool; Marijke Th L Roos; Frank de Wolf; Peter P Koopmans; Peterhans J Van den Broek; Pieter L Meenhorst; Remko van Leeuwen; Joep M A Lange; Peter Reiss
Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy.
AIDS (London, England) 1998;12(1):35-41.
1997: Nadine Pakker; Marijke Th L Roos; Remko van Leeuwen; Menno D De Jong; M Koot; Peter Reiss; Joep M A Lange; Frank Miedema; Sven A Danner; P T A Schellekens
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(5):318-26.
1997: Angelica B Van't Wout; LJ Ran; Menno D De Jong; Margreet Bakker; Remko van Leeuwen; Daan W Notermans; A E Loeliger; Frank de Wolf; Sven A Danner; Peter Reiss; Charles A B Boucher; Joep M A Lange; Hanneke Schuitemaker
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
The Journal of clinical investigation 1997;100(9):2325-32.
1997: Menno D De Jong; Rob J De Boer; Frank de Wolf; NA Foudraine; Charles A B Boucher; Jaap Goudsmit; Joep M A Lange
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
AIDS (London, England) 1997;11(11):F79-84.
1997: P H J Frissen; Frank de Wolf; Peter Reiss; P J M Bakker; Cindy Veenhof; Sven A Danner; Jaap Goudsmit; Joep M A Lange
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma.
The Journal of infectious diseases 1997;176(3):811-4.
1997: Remko van Leeuwen; G J Bonsel; Peter Reiss; Sven A Danner; Joep M A Lange
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
The Journal of infectious diseases 1997;175(6):1344-51.
1997: J Veenstra; PJ Veugelers; IP Keet; A J van der Ven; Frank Miedema; Joep M A Lange; Roel A Coutinho
Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;24(5):936-41.
1997: Joep M A Lange
Current problems and the future of antiretroviral drug trials.
Science (New York, N.Y.) 1997;276(5312):548-50.
1997: Remko van Leeuwen; Joep M A Lange; Monique Nijhuis; Rob Schuurman; Peter Reiss; Sven A Danner; Charles A B Boucher
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
Antiviral therapy 1997;2(2):79-90.
1997: Menno D De Jong; STEFANO VELLA; Andrew Carr; Charles A B Boucher; A Imrie; Martyn French; Jennifer Hoy; S Sorice; S Pauluzzi; F Chiodo; Gerrit Jan Weverling; Marchina E Van Der Ende; P J Frissen; Hugo M Weigel; Robbert H Kauffmann; Joep M A Lange; R Yoon; M Moroni; E Hoenderdos; G Leitz; David A Cooper; D Hall; Peter Reiss
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
The Journal of infectious diseases 1997;175(4):966-70.
1996: Gerrit Jan Weverling; Joep M A Lange; Menno D De Jong; H de Weerd; J Goudsmit; Frank de Wolf
A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals.
Antiviral therapy 1996;1(4):255-63.
1996: Angélique B van 't Wout; Menno D De Jong; Neeltje Kootstra; J Veenstra; Joep M A Lange; Charles A B Boucher; Hanneke Schuitemaker
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis.
The Journal of infectious diseases 1996;174(4):845-9.
1996: Daan W Notermans; Remko van Leeuwen; Joep M A Lange
Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.
Drug safety : an international journal of medical toxicology and drug experience 1996;15(3):176-87.
1996: Marijke Th L Roos; Frank Miedema; A P Meinesz; N A De Leeuw; Nadine Pakker; Joep M A Lange; Roel A Coutinho; P T A Schellekens
Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression.
Clinical and experimental immunology 1996;105(3):409-15.
1996: P H J Frissen; Gerrit Jan Weverling; Erik Endert; J Jansen; H P Sauerwein; Joep M A Lange
Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;12(5):482-8.
1996: J B De Boer; Mirjam A G Sprangers; N K Aaronson; Joep M A Lange; F S van Dam
A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 1996;5(3):339-47.
1996: Menno D De Jong; J Veenstra; Nikolaos I Stilianakis; Rob Schuurman; Joep M A Lange; Rob J De Boer; Charles A B Boucher
Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(11):5501-6.
1996: P H J Frissen; Kees Brinkman; C H Ten Napel; I M van der Ende; I A van Buuren; C A Boucher; Peter Reiss; Joep M A Lange
Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection.
Antiviral therapy 1996;1(2):89-97.
1996: J Veenstra; Rieneke van Praag; Anneke Krol; Pauline M E Wertheim-van Dillen; Hugo M Weigel; P T A Schellekens; Joep M A Lange; Roel A Coutinho; J T M van der Meer
Complications of varicella zoster virus reactivation in HIV-infected homosexual men.
AIDS (London, England) 1996;10(4):393-9.
1996: Menno D De Jong; Rob Schuurman; Joep M A Lange; Charles A B Boucher
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
Antiviral therapy 1996;1(1):33-41.
1996: Menno D De Jong; Charles A B Boucher; G J Galasso; M S Hirsch; E R Kern; Joep M A Lange; D D Richman
Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases.
Antiviral research 1996;29(1):5-29.
1995: M H Godfried; Tom van der Poll; Jan W Mulder; Gerrit Jan Weverling; Erik Endert; Joep M A Lange; Hans P Sauerwein
Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(5):531-9.
1995: J Veenstra; Anneke Krol; Rieneke van Praag; P H J Frissen; P T A Schellekens; Joep M A Lange; Roel A Coutinho; J T M van der Meer
Herpes zoster, immunological deterioration and disease progression in HIV-1 infection.
AIDS (London, England) 1995;9(10):1153-8.
1994: Peter Portegies; Roelien H Enting; Menno D De Jong; Sven A Danner; Peter Reiss; J Goudsmit; Joep M A Lange
AIDS dementia complex and didanosine.
Lancet 1994;344(8924):759.
1993: M Koot; P T A Schellekens; J W Mulder; Joep M A Lange; Marijke Th L Roos; Roel A Coutinho; M Tersmette; Frank Miedema
Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine.
The Journal of infectious diseases 1993;168(3):733-6.
1993: J B de Boer; F S van Dam; Mirjam A G Sprangers; P H J Frissen; Joep M A Lange
Longitudinal study on the Quality of Life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha.
AIDS (London, England) 1993;7(7):947-53.
1993: Charles A B Boucher; Remko van Leeuwen; Kellam Paul; Pauline Schipper; J Tijnagel; Joep M A Lange; Brendan Larder
Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates.
Antimicrobial agents and chemotherapy 1993;37(7):1525-30.
1993: Peter Portegies; Roelien H Enting; Jan de Gans; P R Algra; M M Derix; Joep M A Lange; Jaap Goudsmit
Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands.
AIDS (London, England) 1993;7(5):669-75.
1993: Joep M A Lange; V J Teeuwsen; Charles A B Boucher; A Vahlne; F Barin; SP Tjong-A-Hung; J Dekker; U Parkhede; Frank de Wolf; Jaap Goudsmit
Antigenic variation of the dominant gp41 epitope in Africa.
AIDS (London, England) 1993;7(4):461-6.
1993: Joep M A Lange; Menno D De Jong
The clinical significance of the biological phenotype of HIV.
AIDS clinical review 1993;():1-18.
1993: IP Keet; P Krijnen; M Koot; Joep M A Lange; Frank Miedema; Jaap Goudsmit; Roel A Coutinho
Predictors of rapid progression to AIDS in HIV-1 seroconverters.
AIDS (London, England) 1993;7(1):51-7.
1992: Remko van Leeuwen; Joep M A Lange; EK Hussey; K H Donn; S T Hall; A J Harker; P Jonker; Sven A Danner
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
AIDS (London, England) 1992;6(12):1471-5.
1992: Charles A B Boucher; Joep M A Lange; Frank Miedema; Gerrit Jan Weverling; M Koot; Jan W Mulder; Jaap Goudsmit; Kellam Paul; Brendan Larder; M Tersmette
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
AIDS (London, England) 1992;6(11):1259-64.
1992: Roelien H Enting; Peter Portegies; P R Algra; J Valk; Joep M A Lange
[Progressive multifocal leukoencephalopathy in AIDS].
Nederlands tijdschrift voor geneeskunde 1992;136(11):521-6.
1992: Hanneke Schuitemaker; M Koot; Neeltje Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; Joep M A Lange; J K Schattenkerk; Frank Miedema; M Tersmette
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
Journal of virology 1992;66(3):1354-60.
1992: Marijke Th L Roos; Joep M A Lange; R E de Goede; Roel A Coutinho; P T A Schellekens; Frank Miedema; M Tersmette
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection.
The Journal of infectious diseases 1992;165(3):427-32.
1992: Jan W Mulder; P H J Frissen; P Krijnen; Erik Endert; Frank de Wolf; Jaap Goudsmit; J G Masterson; Joep M A Lange
Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men.
The Journal of infectious diseases 1992;165(3):413-8.
1992: Jan de Gans; Peter Portegies; Peter Reiss; D Troost; Tom Van Gool; Joep M A Lange
Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS.
Journal of acquired immune deficiency syndromes 1992;5(2):137-42.
1992: Charles A B Boucher; E O'Sullivan; Jan W Mulder; C Ramautarsing; Kellam Paul; G Darby; Joep M A Lange; Jaap Goudsmit; Brendan Larder
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.
The Journal of infectious diseases 1992;165(1):105-10.
1991: Menno D De Jong; H J Hulsebosch; Joep M A Lange
Clinical, virological and immunological features of primary HIV-1 infection.
Genitourinary medicine 1991;67(5):367-73.
1991: V J Teeuwsen; Joep M A Lange; R Keet; J K Schattenkerk; CM Debouck; R van den Akker; Jaap Goudsmit; A D Osterhaus
Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers.
AIDS (London, England) 1991;5(8):971-9.
1991: Pol A van der Wouw; Remko van Leeuwen; R H van Oers; Joep M A Lange; Sven A Danner
Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study.
British journal of haematology 1991;78(3):319-24.
1991: Jan W Mulder; P Krijnen; Roel A Coutinho; Margreet Bakker; Jaap Goudsmit; Joep M A Lange
Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment.
Genitourinary medicine 1991;67(3):188-93.
1991: Peter Portegies; P R Algra; Carla E M Hollak; J M Prins; P Reiss; J Valk; Joep M A Lange
Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS.
Lancet 1991;337(8742):680-1.
1991: Menno D De Jong; Joep M A Lange; N J Smits; Peter Reiss
[Pneumocystis carinii infection during prophylaxis with nebulized pentamidine in a patient with AIDS].
Nederlands tijdschrift voor geneeskunde 1991;135(10):424-7.
1991: R de Wit; Sven A Danner; P J M Bakker; Joep M A Lange; J K Eeftinck Schattenkerk; Cindy Veenhof
Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma.
Journal of internal medicine 1991;229(1):35-40.
1991: Joep M A Lange; David A Cooper; Sven A Danner
Antiretroviral treatment: state of the art and future directions.
AIDS (London, England) 1991;5 Suppl 2():S181-8.
1991: Frank de Wolf; Joep M A Lange
Serologic and immunologic markers in the course of HIV-1 infection.
Clinics in dermatology 1991;9(1):1-11.
1991: Rob A Gruters; F G Terpstra; Joep M A Lange; Marijke Th L Roos; T Harkema; J W Mulder; Frank de Wolf; P T A Schellekens; Frank Miedema
Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake.
AIDS (London, England) 1991;5(1):43-7.
1990: Remko van Leeuwen; P J van den Hurk; G Joost Jöbsis; Pol A van der Wouw; Peter Reiss; J K Eeftinck Schattenkerk; Sven A Danner; Joep M A Lange
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection.
Genitourinary medicine 1990;66(6):418-22.
1990: IP Keet; Francis K Lee; G J P van Griensven; Joep M A Lange; Andre J Nahmias; Roel A Coutinho
Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition.
Genitourinary medicine 1990;66(5):330-3.
1990: Charles A B Boucher; M Tersmette; Joep M A Lange; Kellam Paul; R E de Goede; Jan W Mulder; G Darby; Jaap Goudsmit; Brendan Larder
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy.
Lancet 1990;336(8715):585-90.
1990: H J Hulsebosch; F A Claessen; C J van Ginkel; G R Kuiters; J Goudsmit; Joep M A Lange
Human immunodeficiency virus exanthem.
Journal of the American Academy of Dermatology 1990;23(3 Pt 1):483-6.
1990: C E Hollak; Marie José Kersten; J van der Lelie; Joep M A Lange
Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection.
The Netherlands journal of medicine 1990;37(1-2):63-8.
1990: Jan W Mulder; Joep M A Lange; Frank de Wolf; J T Houweling; Margreet Bakker; Roel A Coutinho; Jaap Goudsmit
Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects.
The Netherlands journal of medicine 1990;37(1-2):4-10.
1990: Jan W Mulder; P Krijnen; Jaap Goudsmit; J K Schattenkerk; Peter Reiss; Joep M A Lange
HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
Genitourinary medicine 1990;66(3):138-41.
1990: Joep M A Lange; C A Boucher; Carla E M Hollak; E H Wiltink; P Reiss; E A van Royen; M Roos; S A Danner; J Goudsmit
Failure of zidovudine prophylaxis after accidental exposure to HIV-1.
The New England journal of medicine 1990;322(19):1375-7.
1990: J K Eeftinck Schattenkerk; Joep M A Lange; RP van Steenwijk; Sven A Danner
Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity.
Journal of internal medicine 1990;227(5):359-62.
1990: R de Wit; P J M Bakker; P Reiss; F J Hoek; Joep M A Lange; J Goudsmit; K H Veenhof
Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma.
AIDS (London, England) 1990;4(5):459-62.
1990: Jan de Gans; Peter Portegies; G Tiessens; D Troost; Sven A Danner; Joep M A Lange
Therapy for cytomegalovirus polyradiculomyelitis in patients with AIDS: treatment with ganciclovir.
AIDS (London, England) 1990;4(5):421-5.
1990: Peter Reiss; Joep M A Lange; Anthony de Ronde; Frank de Wolf; J Dekker; CM Debouck; Jaap Goudsmit
Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.
Journal of medical virology 1990;30(3):163-8.
1990: P T A Schellekens; Marijke Th L Roos; Frank de Wolf; Joep M A Lange; Frank Miedema
Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men.
Journal of clinical immunology 1990;10(2):121-7.
1990: Jan W Mulder; Frank de Wolf; Jaap Goudsmit; P A Cload; Roel A Coutinho; A P Fiddian; P T A Schellekens; J van der Noordaa; Joep M A Lange
Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects.
Antiviral research 1990;13(3):127-38.
1990: J W Van Der Pijl; P H J Frissen; Peter Reiss; H J Hulsebosch; J G Van Den Tweel; Joep M A Lange; Sven A Danner
Foscarnet and penile ulceration.
Lancet 1990;335(8684):286.
1990: Peter Reiss; Joep M A Lange; Anthony de Ronde; Frank de Wolf; J Dekker; Sven A Danner; CM Debouck; Jaap Goudsmit
Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes 1990;3(2):115-22.
1989: R de Wit; P Reiss; P J M Bakker; Joep M A Lange; Sven A Danner; K H Veenhof
Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma.
AIDS (London, England) 1989;3(12):847-50.
1989: Pol A van der Wouw; R J Hadderingh; Peter Reiss; H J Hulsebosch; N Walford; Joep M A Lange
Disseminated cat-scratch disease in a patient with AIDS.
AIDS (London, England) 1989;3(11):751-3.
1989: Peter Portegies; Jan de Gans; Joep M A Lange; M M Derix; H Speelman; Margreet Bakker; Sven A Danner; Jaap Goudsmit
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.
BMJ (Clinical research ed.) 1989;299(6703):819-21.
1989: Frank de Wolf; Joep M A Lange; J T Houweling; Jan W Mulder; J Beemster; P T A Schellekens; Roel A Coutinho; J van der Noordaa; Jaap Goudsmit
Appearance of predictors of disease progression in relation to the development of AIDS.
AIDS (London, England) 1989;3(9):563-9.
1989: M Tersmette; Joep M A Lange; R E de Goede; Frank de Wolf; J K Eeftink-Schattenkerk; P T A Schellekens; Roel A Coutinho; J G Huisman; Jaap Goudsmit; F Miedema
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.
Lancet 1989;1(8645):983-5.
1989: M Tersmette; Rob A Gruters; Frank de Wolf; R E de Goede; Joep M A Lange; P T A Schellekens; Jaap Goudsmit; H G Huisman; Frank Miedema
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.
Journal of virology 1989;63(5):2118-25.
1989: Peter Reiss; Anthony de Ronde; Joep M A Lange; Frank de Wolf; J Dekker; CM Debouck; Jaap Goudsmit
Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression.
AIDS (London, England) 1989;3(4):227-33.
1989: Joep M A Lange; Frank de Wolf; Jaap Goudsmit
Markers for progression in HIV infection.
AIDS (London, England) 1989;3 Suppl 1():S153-60.
1989: Joep M A Lange; Frank de Wolf; Jan W Mulder; Roel A Coutinho; J van der Noordaa; Jaap Goudsmit
Markers for progression to acquired immune deficiency syndrome and zidovudine treatment of asymptomatic patients.
The Journal of infection 1989;18 Suppl 1():85-91.
1988: Frank Miedema; A J Petit; F G Terpstra; J K Schattenkerk; Frank de Wolf; B J Al; M Roos; Joep M A Lange; Sven A Danner; Jaap Goudsmit
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.
The Journal of clinical investigation 1988;82(6):1908-14.
1988: Frank de Wolf; M Roos; Joep M A Lange; J T Houweling; Roel A Coutinho; J van der Noordaa; P T A Schellekens; Jaap Goudsmit
Decline in CD4+ cell numbers reflects increase in HIV-1 replication.
AIDS research and human retroviruses 1988;4(6):433-40.
1988: Jan de Gans; Joep M A Lange; M M Derix; Frank de Wolf; Bram Ongerboer de Visser; J Goudsmit
[Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS].
Nederlands tijdschrift voor geneeskunde 1988;132(36):1656-60.
1988: Frank de Wolf; Joep M A Lange; J T Houweling; Roel A Coutinho; P T A Schellekens; J van der Noordaa; Jaap Goudsmit
Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men.
The Journal of infectious diseases 1988;158(3):615-22.
1988: P J M Bakker; Sven A Danner; Joep M A Lange; K H Veenhof
Etoposide for epidemic Kaposi's sarcoma: a phase II study.
European journal of cancer & clinical oncology 1988;24(6):1047-8.
1988: Frank de Wolf; Joep M A Lange; Jaap Goudsmit; P Cload; Jan de Gans; P T A Schellekens; Roel A Coutinho; A P Fiddian; J van der Noordaa
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.
Lancet 1988;1(8582):373-6.
1988: Jan de Gans; Joep M A Lange; M M Derix; Frank de Wolf; J K Eeftinck Schattenkerk; Sven A Danner; Bram Ongerboer de Visser; P Cload; Jaap Goudsmit
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine.
AIDS (London, England) 1988;2(1):37-40.
1988: Joep M A Lange; J V Parry; Frank de Wolf; P P Mortimer; Jaap Goudsmit
Diagnostic value of specific IgM antibodies in primary HIV infection.
AIDS (London, England) 1988;2(1):31-5.
1988: Jaap Goudsmit; Joep M A Lange; Laura A Smit; Margreet Bakker; Bep Klaver; Sven A Danner; Roel A Coutinho
Serodiagnostic profiles of HIV and HIV pathogenesis in vivo.
Haematologia 1988;21(2):71-81.
1988: M Tersmette; P Nico Lelie; Cees L van der Poel; M R Wester; R E de Goede; Joep M A Lange; Frank Miedema; J G Huisman
Confirmation of HIV seropositivity: comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture.
Journal of medical virology 1988;24(1):109-16.
1988: J K Eeftinck Schattenkerk; Sven A Danner; Joep M A Lange; D A Paul; C J van Boxtel; F Miedema; P T A Schellekens; Jaap Goudsmit
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study.
Archives of internal medicine 1988;148(1):209-11.
1987: Frank de Wolf; Jaap Goudsmit; D A Paul; Joep M A Lange; C Hooijkaas; P T A Schellekens; Roel A Coutinho; J van der Noordaa
Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia.
British medical journal (Clinical research ed.) 1987;295(6598):569-72.
1987: J van der Lelie; Joep M A Lange; J J Vos; C M van Dalen; Sven A Danner; Albert E G Kr von dem Borne
Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection.
British journal of haematology 1987;67(1):109-14.
1987: Joep M A Lange; Frank de Wolf; W J Krone; S A Danner; R A Coutinho; Jaap Goudsmit
Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline.
AIDS (London, England) 1987;1(3):155-9.
1987: Sven A Danner; J K Eeftinck Schattenkerk; Joep M A Lange; RP van Steenwijk; Jan de Gans; T R Menardi; T R Meinardi
[Disease symptoms and clinical course in the first 100 patients with AIDS].
Nederlands tijdschrift voor geneeskunde 1987;131(34):1474-81.
1987: Jaap Goudsmit; Joep M A Lange; W J Krone; Marcel B M Teunissen; L G Epstein; Sven A Danner; H van den Berg; C Breederveld; Laura A Smit; Margreet Bakker
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy.
Journal of virological methods 1987;17(1-2):19-34.
1987: Joep M A Lange; D A Paul; Frank de Wolf; R A Coutinho; Jaap Goudsmit
Viral gene expression, antibody production and immune complex formation in human immunodeficiency virus infection.
AIDS (London, England) 1987;1(1):15-20.
1986: Joep M A Lange; D A Paul; H G Huisman; Frank de Wolf; H van den Berg; Roel A Coutinho; S A Danner; J van der Noordaa; Jaap Goudsmit
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.
British medical journal (Clinical research ed.) 1986;293(6560):1459-62.
1986: Jaap Goudsmit; Frank de Wolf; D A Paul; L G Epstein; Joep M A Lange; W J Krone; H Speelman; E C Wolters; J Van der Noordaa; J M Oleske
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection.
Lancet 1986;2(8500):177-80.